Zydus Lifesciences Limited (ZYDUSLIFE.NS)

INR 983.75

(0.43%)

Market Cap (In INR)

989.87 Billion

Revenue (In INR)

190.21 Billion

Net Income (In INR)

38.59 Billion

Avg. Volume

2.5 Million

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
648.15-1324.3
PE
-
EPS
-
Beta Value
0.433
ISIN
INE010B01027
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Punit Patel
Employee Count
-
Website
https://www.zyduslife.com
Ipo Date
2002-07-01
Details
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

More Stocks